Augmentin Speed Of Action Statistics

In this post, we will explore key statistics and facts about Augmentin, a widely-used antibiotic medication. From its dosing regimens to common side effects, pharmacokinetics to clinical indications, Augmentin plays a crucial role in treating various infections. Let’s dive into the data to understand more about this essential drug.

Statistic 1

"The typical dose of Augmentin for adults is 250-500mg every 8 hours or 500-875 mg every 12 hours, depending on the infection being treated."

Statistic 2

"Augmentin is mentioned in at least 100 studies on PubMed.gov"

Statistic 3

"Augmentin is a combination of amoxicillin (a penicillin derivative) and clavulanate potassium."

Statistic 4

"Augmentin is used to treat various infections, including those of the ear, nose, throat, skin and urinary tract."

Statistic 5

"The half-life of Augmentin in healthy subjects is approximately 1 hour."

Statistic 6

"Augmentin takes around 2 hours to reach peak plasma levels."

Statistic 7

"Augmentin is available in four different dosage forms including immediate-release tablet, extended-release tablet, chewable tablet, and reconstitutable suspension."

Statistic 8

"The most common side effects of Augmentin are diarrhoea, rash, and nausea which affect around 3-16% of patients."

Statistic 9

"Augmentin is on the World Health Organisation’s List of Essential Medicines"

Statistic 10

"Augmentin was approved by the FDA in 1984."

In conclusion, Augmentin is a widely-used antibiotic medication that combines amoxicillin with clavulanate potassium to effectively treat a variety of infections. With a quick onset of action, reaching peak plasma levels within 2 hours, Augmentin offers rapid relief to patients. Its broad spectrum of applications, availability in different dosage forms, and inclusion in essential medicines lists underscore its importance in healthcare. Despite some common side effects, Augmentin’s established efficacy and track record since FDA approval in 1984 make it a valuable treatment option with a strong research backing.